A New Player in Eczema Treatment

Eucrisa (crisaborole) approved to treat eczema

(RxWiki News) The US Food and Drug Administration has approved a new treatment for a common skin disease called eczema.

This new treatment is Eucrisa (crisaborole). It was approved to treat patients 2 years old and older with mild to moderate atopic dermatitis (eczema).

Atopic dermatitis, the most common of the many types of eczema, usually starts in childhood but can last throughout adulthood.

The typical signs and symptoms of atopic dermatitis include red, scaly skin, which may also include crusted bumps. The skin is itchy, and scratching leads to swelling and cracking of the skin. Patients may notice a clear fluid being released from the skin. As a result, the skin becomes thick.

Eucrisa is available as an ointment and is applied twice a day.

Crisaborole received approval after showing its safety and benefit in two placebo-controlled trials.

Common side effects of this medication include pain (burning or stinging) at the application site.

Eucrisa may cause serious side effects, which include serious allergic reactions. As a result, it should not be used by those who have had a hypersensitivity reaction to crisaborole.

Crisaborole is manufactured by Anacor Pharmaceuticals.